Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Oct 5, 2011

Premium

Synthetic Genomics Vaccines, which focuses on developing vaccines using sequencing and synthetic genomic technologies, has appointed Sammy Farah as president.

Farah joins the company from Immune Design, where he was chief business officer. Previously, he was at Versant Ventures, where he specialized in biotechnology investing; and at Merck, where he led technology support for multiple commercial vaccines.

He holds an MBA from the Wharton School at University of Pennsylvania, a PhD in biochemical engineering from Stanford University, and a BS in biochemical engineering from MIT.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.